GeneHealth - Your precision medicine

Cycloplegia

Disease Details

Family Health Simplified

Buy Membership

Description: Cycloplegia refers to the paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation.
Type: Cycloplegia is not typically classified as a genetic disease, making its transmission not directly related to genetics. It is usually caused by pharmacological agents used to paralyze the ciliary muscle of the eye or as a result of trauma or neurological conditions. Therefore, there is no specific type of genetic transmission associated with cycloplegia.
Signs And Symptoms: Signs and symptoms of cycloplegia include:

1. Inability to focus on near objects (due to paralysis of the ciliary muscle).
2. Blurred vision, especially for close-up tasks.
3. Dilation of the pupil (mydriasis), leading to increased light sensitivity.
4. Eye discomfort or pain due to the sudden change in vision.
5. Potential headaches due to eye strain from attempting to focus.

These symptoms result from the paralysis of the ciliary muscle, which controls lens accommodation, commonly induced by certain medications during eye examinations.
Prognosis: Cycloplegia is the paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation and the inability to focus on near objects. The prognosis for cycloplegia largely depends on its underlying cause:

- **Drug-Induced Cycloplegia**: If caused by medications (such as cycloplegic eye drops used during eye examinations), the condition is usually temporary and resolves once the effects of the drug wear off, typically within a few hours to a day.

- **Traumatic or Pathological Cycloplegia**: If caused by trauma or disease affecting the ciliary muscle or nerves (such as third nerve palsy), the prognosis varies. Recovery may depend on the extent of the injury or effectiveness of treatment for the underlying condition.

Overall, temporary cycloplegia induced by medication has an excellent prognosis, whereas cycloplegia from other causes may require further medical assessment and intervention to determine the outcome.
Onset: Cycloplegia is the paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation. Its onset and duration can vary based on the cause and treatment used. Typically, cycloplegic drugs like atropine can cause cycloplegia within 30 to 60 minutes of administration, and the effects may last from a few hours to up to two weeks, depending on the specific drug and dosage. Nan is not applicable in this context.
Prevalence: Cycloplegia, a condition characterized by paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation, does not have a well-documented prevalence in the general population. It is most commonly induced intentionally for diagnostic or therapeutic purposes, such as during an eye examination, using cycloplegic drugs. Consequently, the prevalence of cycloplegia as an unintentional or pathological condition is not widely reported or characterized in medical literature.
Epidemiology: Cycloplegia is a paralysis of the ciliary muscle of the eye, which results in a loss of accommodation. The epidemiology data for cycloplegia are not extensively detailed, as it is often a temporary condition intentionally induced in a clinical setting rather than a naturally occurring phenomenon. It is primarily used by ophthalmologists to facilitate the examination of the eye's internal structures or to treat certain eye conditions. Naturally occurring cycloplegia may be associated with trauma, systemic disease, or certain medications, but specific prevalence rates are not well-documented.
Intractability: Cycloplegia is the paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation and the inability to focus on near objects. It is not inherently intractable. The condition is often temporary and can be induced by certain medications, such as cycloplegics used during eye examinations. In cases where cycloplegia is caused by an underlying disease or injury, the prognosis and treatment may vary depending on the specific cause.
Disease Severity: Cycloplegia is not classified as a disease but rather a condition characterized by paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation. It can be caused by certain medications or eye drops used during eye examinations, or due to trauma or neurological disorders. If the paralysis is temporary, it is not typically severe and resolves once the effect of the medication wears off. However, if caused by trauma or underlying conditions, proper medical evaluation will be necessary to determine the severity and appropriate treatment.
Healthcare Professionals: Disease Ontology ID - DOID:10033
Pathophysiology: Cycloplegia is a condition characterized by paralysis of the ciliary muscle of the eye, leading to a loss of accommodation. The pathophysiology involves disruption in the normal function of the ciliary muscle, which can be due to pharmacologic agents (such as cycloplegic drugs like atropine or tropicamide), trauma, or neurological disorders. These agents or conditions interfere with the muscarinic receptors responsible for muscle contraction, rendering the eye unable to change lens shape for focusing on near objects. Consequently, individuals with cycloplegia often experience difficulty with near vision tasks.
Carrier Status: Cycloplegia refers to the paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation. This condition is not typically associated with a carrier status, as it is generally caused by factors such as pharmacologic agents (e.g., cycloplegic drugs like atropine), trauma, or certain neurological conditions. It is not known to be inherited in a manner that would involve carriers.
Mechanism: Cycloplegia is the paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation. Here are the key points:

### Mechanism:
1. **Ciliary Muscle Paralysis**: When the ciliary muscle is paralyzed, it cannot contract to change the shape of the lens for near vision, causing a loss of accommodation.
2. **Effect on Pupil**: Cycloplegia is often accompanied by mydriasis (pupil dilation) because the same drugs that induce cycloplegia can also affect the muscles that control pupil size.

### Molecular Mechanisms:
1. **Antimuscarinic Agents**: Cycloplegia is often induced by antimuscarinic drugs like atropine, cyclopentolate, and tropicamide.
- **Muscarinic Receptor Blockade**: These drugs block muscarinic acetylcholine receptors (specifically M3 receptors) on the ciliary muscle, preventing acetylcholine from binding and inhibiting muscle contraction.
2. **Inhibition of Acetylcholine**: By blocking the action of acetylcholine, these drugs prevent the ciliary muscle from adjusting the lens for near vision, leading to a state of fixed focus for distant vision.
3. **Adrenergic Agonists**: Some agents, like phenylephrine, can also cause cycloplegia indirectly by stimulating adrenergic receptors and inducing mydriasis, which can inhibit accommodation by stretching the ciliary muscle.

Through these pathways, cycloplegia can be effectively induced for clinical purposes, such as dilating the pupil for an eye examination or managing certain eye conditions.
Treatment: Cycloplegia is the paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation. The treatment typically involves the use of cycloplegic eye drops, which are medications that temporarily paralyze the ciliary muscle and dilate the pupil. Common agents include atropine, cyclopentolate, and tropicamide. The specific choice of medication and dosage depends on the underlying cause and the severity of the condition. Additional treatments may address the underlying cause, such as managing inflammation or trauma, if present.
Compassionate Use Treatment: Cycloplegia is a condition characterized by paralysis of the ciliary muscle, resulting in a loss of accommodation and the inability to focus on close objects.

For compassionate use, off-label, or experimental treatments for cycloplegia:

1. **Compassionate Use Treatments:**
- These treatments are typically considered when no other treatment options are available. Specific drugs or interventions under compassionate use must be reviewed on a case-by-case basis by regulatory authorities and healthcare providers.

2. **Off-Label Treatments:**
- **Pilocarpine:** Though primarily used to treat glaucoma, pilocarpine is a miotic (pupil-constricting) agent that can sometimes help in reversing cycloplegia.
- **Brimonidine (Alphagan):** Typically used for glaucoma, this drug may have off-label utility in managing certain symptoms associated with cycloplegia.

3. **Experimental Treatments:**
- **Gene Therapy:** Research is ongoing in the genetic manipulation arena to address underlying causes of muscle paralysis, which may eventually include treatments for cycloplegia.
- **Stem Cell Therapy:** Experimental studies are exploring the use of stem cells to regenerate or repair the ciliary muscle function.

Always consult a healthcare professional for the most accurate diagnosis and treatment options for specific medical conditions.
Lifestyle Recommendations: Lifestyle recommendations for managing cycloplegia, which is paralysis of the ciliary muscle of the eye leading to a loss of accommodation, may include:

1. **Eye Protection**: Wear sunglasses to protect your eyes from bright light and glare since pupils may be dilated, increasing sensitivity to light.
2. **Visual Aids**: Use corrective lenses or prescription glasses as recommended by your ophthalmologist to help with focusing issues.
3. **Limit Eye Strain**: Avoid activities that require prolonged focus like reading fine print or using digital screens for extended periods.
4. **Frequent Breaks**: If your work requires close-up tasks, take regular breaks to rest your eyes.
5. **Healthy Diet**: Maintain a balanced diet rich in vitamins A, C, and E, and zinc to support overall eye health.
6. **Hydration**: Keep hydrated to ensure optimal eye function and reduce dryness.
7. **Routine Eye Exams**: Regular check-ups with an eye care professional to monitor and manage the condition effectively.

These recommendations support better visual comfort and eye health while managing cycloplegia.
Medication: Cycloplegia is a condition where the ciliary muscle of the eye is paralyzed, resulting in a loss of accommodation. It can be induced by certain medications, primarily cycloplegic agents. Common medications used to induce cycloplegia include:

1. **Atropine**
2. **Cyclopentolate**
3. **Tropicamide**
4. **Homatropine**
5. **Scopolamine**

These drugs are often used during eye examinations to temporarily paralyze the ciliary muscle and facilitate the measurement of refractive errors.
Repurposable Drugs: Repurposable drugs for cycloplegia include:

1. **Atropine** - traditionally used for pupil dilation and to temporarily paralyze the ciliary muscle.
2. **Cyclopentolate** - commonly used in ophthalmic examinations to achieve cycloplegia and mydriasis.
3. **Tropicamide** - another short-acting agent used for diagnostic purposes in eye exams.

These drugs are primarily anticholinergics, blocking the muscarinic receptors in the eye to prevent accommodation and allow for detailed examination of the retina and other interior structures.
Metabolites: Cycloplegia is a condition where the ciliary muscle of the eye becomes paralyzed, resulting in a loss of accommodation. This typically prevents the eye from focusing on near objects. Cycloplegia is often induced intentionally using cycloplegic drugs during eye examinations. As of now, there isn't specific information available about endogenous metabolites directly associated with cycloplegia, since it is typically a drug-induced condition and not a metabolic disorder.
Nutraceuticals: There is currently no strong evidence to support the use of nutraceuticals (foods or food products that provide health and medical benefits) specifically for the treatment or management of cycloplegia, which is paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation. The primary treatments usually involve addressing the underlying cause and using glasses or contact lenses to correct vision issues. Advanced treatments sometimes involve pharmacological agents like cycloplegic drops (e.g., atropine). Keep in mind, existing nutraceuticals may support overall eye health but are not a direct treatment for cycloplegia.
Peptides: Cycloplegia is a condition characterized by the paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation. This can be induced pharmacologically or occur due to disease or trauma.

Peptides: Specific peptides are not typically used in the treatment or diagnosis of cycloplegia. The condition is usually managed with cycloplegic drugs such as atropine, cyclopentolate, or tropicamide, which are anticholinergic agents that temporarily paralyze the ciliary muscle.

Nanotechnology (Nan): Nanotechnology has not been widely adopted in the clinical management of cycloplegia. Research into nanotechnology in ophthalmology is growing, with potential applications in drug delivery systems and improved formulations of traditional medications. However, its use specifically for cycloplegia remains limited at this time.